
    
      Multicenter, open-label, phase 1, dose escalation study to determine the maximum tolerated
      dose on both once daily (QD) and twice daily (BID) schedules.

      Patients may continue to receive OSI-930 until one of the following occurs: disease
      progression, adverse event requiring withdrawal, failure to recover from toxicity despite a
      14-day dosing interruption, medical or ethical reasons, patient request, or patient death.
    
  